

## Appendix I: Infusion Pump Charts

**Dopamine Infusion Pump Chart**  
(Dopamine 400 mg in 500 mL [800 µg/mL]<sup>a</sup>)

<i>Dosage</i> (µg/kg/min)	<i>Rate (mL/h [pump] or drops/min [microdrip])<sup>b</sup></i> <i>for different body weights (kg)</i>						
	40	50	60	70	80	90	100
1.0	3	4	5	5	6	7	8
1.5	5	6	7	8	9	10	11
2.0	6	8	9	11	12	14	15
2.5	8	9	11	13	15	17	19
3.0	9	11	14	16	18	20	23
3.5	11	13	16	18	21	24	26
4.0	12	15	18	21	24	27	30
4.5	14	17	20	24	27	30	34
5.0	15	19	23	26	30	34	38
6.0	18	23	27	32	36	41	45
7.0	21	26	32	37	42	47	53
8.0	24	30	36	42	48	54	60
9.0	27	34	41	47	54	61	68
10.0	30	38	45	53	60	68	75
12.0	36	45	54	63	72	81	90
15.0	45	56	68	79	90	101	113
20.0	60	75	90	105	120	135	150
25.0	75	94	113	131	150	169	188

<sup>a</sup>The above rates apply only for an 800 mg/L concentration of dopamine. If a different concentration must be used, appropriate adjustments in rates should be made. Start at 1 µg/kg/min; ideal dose range 5–7.5 µg/kg/min. Maximum suggested 10 µg/kg/min. Dopamine should be given via a central line.

<sup>b</sup>Use chart for (1) pump (mL/h) or (2) microdrip (drops/min). Example: 60-kg patient at 2.0 µg/kg/min: (1) set pump at 9 mL/h; (2) run microdrip solution at 9 drops/min.

**Nitroprusside Infusion Pump Chart**  
(Nitroprusside 50 mg [1 vial] in 100 mL [500 mg/mL]<sup>a</sup>)

Dosage ( $\mu\text{g}/\text{kg}/\text{min}$ )	Rate (mL/h) for different body weights (kg)						
	40	50	60	70	80	90	100
0.2	1	1	1	2	2	2	2
0.5	2	3	4	4	5	5	6
0.8	4	5	6	7	8	9	10
1.0	5	6	7	8	10	11	12
1.2	6	7	9	10	12	13	14
1.5	7	9	11	13	14	16	18
1.8	9	11	13	15	17	19	22
2.0	10	12	14	17	19	22	24
2.2	11	13	16	18	21	24	26
2.5	12	15	18	21	24	27	30
2.8	13	17	20	23	27	30	34
3.0	14	18	22	25	29	32	36
3.2	15	19	23	27	31	35	38
3.5	17	21	25	29	34	38	42
3.8	18	23	27	32	36	41	46
4.0	19	24	29	34	38	43	48
4.5	22	27	32	38	43	49	54
5.0	24	30	36	42	48	54	60
6.0	29	36	43	50	58	65	72

<sup>a</sup>The above rates apply only for a 500 mg/L concentration of nitroprusside. If a different concentration must be used, appropriate adjustments in rates should be made. Start at 0.2  $\mu\text{g}/\text{kg}/\text{min}$ . Increase slowly. Average dose 3  $\mu\text{g}/\text{kg}/\text{min}$ . Usual dose range 0.5–5.0  $\mu\text{g}/\text{kg}/\text{min}$ .

**Continuous Infusion Heparin<sup>a</sup>**





Rate (mL/h)	Units (/h)	Units (/24 h)	Volume (mL/24 h)
1. 21	840	20,160	
2. 25	1000	24,000	
3. 28	1120	26,880	600
4. 30	1200	28,800	
5. 32	1280	30,720	
6. 34	1360	32,640	
7. 36	1440	34,560	
8. 38	1520	36,480	912
9. 40	1600	38,400	
10. 42	1680	40,320	
11. 44	1760	42,240	

<sup>a</sup>20,000 heparin in 500 mL 5% dextrose; 1 mL = 40 units. Start with infusion no. 1 for patients < 67 kg for acute MI, and choose no. 2 for patients > 67 kg. Choose the appropriate alternative depending on the PTT value. Nos. 3 to 10 are mainly for pulmonary embolism and massive DVT.

Start with infusion no. 2 and choose the appropriate alternative depending on the once-daily PTT value.

## Appendix II: Drug Index

The Drug Index gives the generic drug name in lowercase; the pharmaceutical trade names begin with a capital letter. C, Canada when different from USA; F, France; G, Germany.

 USA	 UK	 Europe	 Japan
<b>ACE inhibitors</b>			
benazepril Lotensin		benazepril Briem (F), Cibace Cibacin Lotensine	benazepril
captopril Capoten	captopril Capoten	captopril Captolane (F) Lopril (F) Loprin (G) Tensobon (G)	captopril Captopril
cilazapril Inhibace	cilazapril Vaspace	cilazapril Dynorm (G)	cilazapril
enalapril Vasotec	enalapril Innovace	enalapril Pres (G) Renitec (F) Xanef (G)	enalapril Renivace
fosinopril Monopril	fosinopril Staril	fosinopril Dynacil (G) Eliten (I)	fosinopril
lisinopril Prinivil Zestril	lisinopril Carace Zestril	lisinopril Longes Zestril (F)	lisinopril
moexipril	moexipril	moexipril	

From: *Contemporary Cardiology: Cardiac Drug Therapy, Seventh Edition*  
M. Gabriel Khan © Humana Press Inc., Totowa, NJ



USA



UK



Europe



Japan

**ACE inhibitors (continued)**

Univasc perindopril Coversyl	Perdix perindopril Coversyl	perindopril Acertil Coversum Pexum	perindopril
quinapril Accupril	quinapril Accupro	quinapril Accuprin Acuitel Korec (F)	quinapril
ramipril Altace	ramipril Tritace	ramipril Delix Ramace Triatec (F) spirapril Renpress Sandopril	rarnipril  spirapril
trandolapril Mavik	trandolapril Gopten Odrik	trandolapril Gopten  zefenopril	trandolapril  zefenopril
<b>Angiotensin II receptor blockers</b> candesartan Atacand	candesartan Amias		candesartan
eprosartan Teveten	eprosartan		
irbesartan Avapro	irbesartan Aprovel		
losartan Cozaar	losartan Cozaar	losartan Cozaar	losartan
olmesartan Benicar	olmesartan	olmesartan	
telmisartan Micardis	telmisartan	telmisartan	telmisartan
valsartan Diovan	valsartan Diovan	valsartan Diovan	valsartan



USA



UK



Europe



Japan

**Antiarrhythmics**

adenosine Adenocard	adenosine Adenocor	adenosine	adenosine
amiodarone Cordarone	amiodarone Cordarone X	amiodarone	amiodarone
disopyramide Norspace Rythmodan	disopyramide Dirythmin SA Rythmodan	disopyramide	disopyramide
flecainide Tambocor	flecainide Tambocor	flecainide	flecainide
mexiletine Mexitil	mexiletine Mexitil	mexiletine	mexiletine
procainamide Pronestyl	procainamide Pronestyl	procainamide	procainamide
propafenone Rythmol	propafenone Arythmol	propafenone Rytmonorm	propafenone
quinidine	quinidine	quinidine	quinidine
sotalol Betapace Sotacor	sotalol Beta-cardone Sotacor	sotalol Sotacor	sotalol

**Anticoagulants**

dalteparin Fragmin	dalteparin	dalteparin	
enoxaparin Lovenox	enoxaparin Clexane	enoxaparin	enoxaparin
warfarin Coumadin	warfarin Marevan	warfarin	warfarin

**Antiplatelet agents**

abciximab ReoPro	abciximab ReoPro		
aspirin	aspirin	aspirin	aspirin
clopidogrel Plavix			

*(continued)*



USA



UK



Europe



Japan

**Antiplatelet agents (continued)**

dipyridamole	dipyridamole	dipyridamole	dipyridamole
Persantine	Persantine Persantin Retard	Persantine Cardoxin	
ebtifibatide Integrilin			
tirofiban Aggrastat			

**Beta-blockers**

acebutolol Sectral Monitan	acebutolol Sectral	acebutolol Prent Neptall Sectral	acebutolol
atenolol Tenormin	atenolol Tenormin	atenolol Tenormine (F) Tenormin Bêtatop	atenolol
betaxolol Kerlone	betaxolol Kerlone	betaxolol Kerlone	betaxolol
bisoprolol Zebeta (Ziac)	bisoprolol Emcor Monocor	bisoprolol	bisoprolol
carteolol Catrol		carteolol	carteolol
carvedilol Coreg	carvedilol Eucardic celiprolol Celectol	celiprolol Celector Celectol (F)	carvedilol celiprolol
esmolol Brevibloc	esmolol Brevibloc	esmolol Brevibloc	
labetalol Normodyne	labetalol Trandate	labetalol Trandate	labetalol Trandate
metoprolol Betaloc	metoprolol Betaloc	metoprolol	metoprolol



USA



UK



Europe



Japan

**Beta-blockers (continued)**

Lopressor Toprol XL	Lopressor	Lopressor Metohexal Séloken	
nadolol Corgard	nadolol Corgard	nadolol Corgard Solgol (G)	nadolol
nebivolol Nebilit	nebivolol Nebilit	nebivolol Nebilit	nebivolol
propranolol Inderal	propranolol Inderal Inderal-LA	propranolol Angilol Avolacardyl (F) Berkolol Dociton (G) Efektolol	propranolol
sotalol Sotacor	sotalol Sotacor	sotalol Sotacor	sotalol
Betapace	Beta-Cardone	Sotalex (G) Sotalex (F)	
timolol Blocadren	timolol Blocadren Betim	timolol Timacor (F) Temserin	timolol
<b>Calcium antagonists</b>			
amlodipine Norvasc	amlodipine Istin	amlodipine Amlor (F) Norvasc	amlodipine
diltiazem Cardizem CD Tiazac	diltiazem Adizem XL Tildiem LA Viazem XL	diltiazem Dilrene (F) Dilzem Herbesser	diltiazem
felodipine Plendil Renedil	felodipine Plendil	felodipine Flodil (F)	felodipine
isradipine	isradipine	isradipine	

*(continued)*



USA



UK



Europe



Japan

**Calcium antagonists (continued)**

DynaCirc	Prescal lacidipine Montens	Flodil (F) lacidipine	lacidipine
nicardipine Cardene Cardene SR	nicardipine Cardene Cardene SR		nicardipine
nifedipine	nifedipine	nifedipine	nifedipine
Adalat CC Adalat XL (C) Procardia XL	Adalat LA Nifensar XL	Adalat	
nisoldipine Sular	nisoldipine Syscor	nisoldipine Baymycard nitrendipine Baypress	
verapamil Isoptin SR Calan SR Covera-HS Chronovera (C)	verapamil Securon SR Univer Cordilox	verapamil Isoptin Isoptine Arpamyl	verapamil
<b>Digitalis</b> digitoxin digoxin Lanoxin	digitoxin digoxin Lanoxin	digitoxin digoxin Lanoxin Lanoxine	digitoxin digoxin
<b>Diuretics</b> bendrofluazide Naturetin	bendrofluazide Aprinox Neo-Naclex	bendrofluazide	
bumetanide Bumex Burinex	bumetanide Burinex	bumetanide	bumetanide
chlorothiazide Diuril	chlorothiazide Saluric	chlorothiazide Saluric	
chlorthalidone Hygroton	chlorthalidone Hygroton Cyclopentazide Navidrex	chlorthalidone Hygroton Cyclopentazide Navidrex	chlorthalidone





USA



UK



Europe



Japan

**Diuretics (continued)**

furosemide Lasix	frusemide Lasix	frusemide	furosemide
hydrochlorothiazide	hydrochlorothiazide	hydrochlorothiazide	hydrochlorothiazide

Esidrix Hydro Diuril	Esidrex Hydro Saluric		
-------------------------	--------------------------	--	--

indapamide Lozol Lozide (C)	indapamide Natramid Natrilix	indapamide Natrillix	indapamide
-----------------------------------	------------------------------------	-------------------------	------------

metolazone Zaroxolyn	metolazone Metenix	metolazone Diulo	
-------------------------	-----------------------	---------------------	--

spironolactone Aldactone	spironolactone Aldactone		
-----------------------------	-----------------------------	--	--

toremide Demadex	torasemide Torem		
---------------------	---------------------	--	--

**Combination drugs**

hydrochlorothiazide plus amiloride Moduretic Moduret (C)	co-amilozide Amil-Co Moduret 25 Moduretic		hydrochlorothiazide plus amiloride
---	--	--	---------------------------------------

hydrochlorothiazide plus triamterene Dyazide	hydrochlorothiazide plus triamterene Dyazide		hydrochlorothiazide plus triamterene
--	--	--	---

**Lipid-lowering agents****Statins**

atrovastatin Lipitor	atrovastatin Lipitor	atrovastatin	atrovastatin
-------------------------	-------------------------	--------------	--------------

fluvastatin Lescol	fluvastatin Lescol	fluvastatin Lipur (F)	fluvastatin
-----------------------	-----------------------	--------------------------	-------------

lovastatin Mevacor			
-----------------------	--	--	--

pravastatin Pravachol	pravastatin Lipostat	pravastatin Elisor Vasten	pravastatin
--------------------------	-------------------------	------------------------------	-------------

rosuvastatin Crestor	rosuvastatin Crestor	rosuvastatin Cresto	rosuvastatin
-------------------------	-------------------------	------------------------	--------------

*(continued)*



USA



UK



Europe



Japan

**Lipid-lowering agents (continued)****Statins**

simvastatin Zocor	simvastatin Zocor	simvastatin Zocor Lodales	simvastatin
----------------------	----------------------	---------------------------------	-------------

**Resins**

cholestyramine Questran	cholestyramine Questran Questran Light	cholestyramine Questran Cuemrid	cholestyramine
----------------------------	--	---------------------------------------	----------------

colestipol Colestid	colestipol Colestid	colestipol	
------------------------	------------------------	------------	--

**Fibrates**

bezafibrate Bezalip Bezalip Mono	bezafibrate Bezalip Bezalip Mono	bezafibrate	bezafibrate
--	--	-------------	-------------

fenofibrate Lipidil	fenofibrate Lipantil Micro	fenofibrate	fenofibrate
------------------------	-------------------------------	-------------	-------------

gemfibrozil Lopid	gemfibrozil Lopid	gemfibrozil Lopid Lipur (E)	gemfibrozil
----------------------	----------------------	-----------------------------------	-------------

**Nitrates**

isosorbide dinitrate Isordil	isosorbide dinitrate Cedocard Retard Isocard Isordil Sorbid SA Sorbitrate	isosorbide dinitrate	isosorbide dinitrate
---------------------------------	--	----------------------	----------------------

isosorbide mononitrate Imdur	isosorbide mononitrate Imdur	isosorbide mononitrate	isosorbide mononitrate
------------------------------------	------------------------------------	---------------------------	---------------------------

nitroglycerin nitroglycerin Nitrolingual spray	nitroglycerine glyceryl trinitrate Nitrolingual spray Coro-nitrospray	nitroglycerine	nitroglycerin
--	--	----------------	---------------

# INDEX

---

## A

- Abciximab,
  - dosing, 339
  - indications, 339, 340
  - properties, 338
  - trade names, 399
- Abciximab, unstable angina management, 174
- Acebutolol,
  - dosing, 8
  - mortality reduction studies, 4
  - overview, 23
  - pharmacologic properties, 10
  - trade names, 400
- ACE inhibitors, *see* Angiotensin-converting enzyme inhibitors
- Acetazolamide,
  - overview, 94
  - trade names and dosing, 86
- ACUITY, findings, 383, 384
- Acute coronary syndrome, *see* Unstable angina
- Adenosine,
  - atrioventricular nodal reentrant tachycardia management, 254
  - contraindications, 254
  - dosing, 254
  - drug interactions, 365
  - lactation safety, 358
  - pregnancy and drug safety, 356
  - trade names, 399
- $\beta$ -Adrenergic receptors,
  - classification, 4–6
  - tissue distribution, 4–6
- AF, *see* Atrial fibrillation
- AFFIRM, findings, 389
- African Americans,
  - heart failure studies, 245, 246
  - hypertension drug selection, 147–154
- A-HeFT, findings, 386
- Albuterol, cardiac effects, 376
- Aldactazide, formulation and dosing, 93
- Aldactide, formulation and dosing, 93
- Aldosterone antagonists,
  - hallmark clinical trials, 385, 386
  - heart failure management, 98, 99, 222, 223, 245
- ALLHAT, findings, 386, 387
- Alpha<sub>1</sub>-blockers,
  - contraindications, 127
  - hypertension management, 126, 127
- Amiloride, trade names and dosing, 86
- Aminophylline, pulmonary edema management, 237
- Amiodarone,
  - action, 277
  - adverse effects, 278–280
  - atrioventricular nodal reentrant tachycardia management, 258
  - cardiac arrest management, 291, 292
  - dosing, 277
  - drug interactions, 279, 365, 366
  - indications, 278
  - lactation safety, 358
  - overview, 277
  - pharmacokinetics, 277, 278
  - pregnancy and drug safety, 356
  - trade names, 399
- Amlodipine,
  - angina management, 163
  - combination therapy, 77
  - heart failure management, 221
  - hypertension management, 124
  - overview, 73
  - trade names, 401
  - unstable angina management, 172
- Amphotericin B, fungal endocarditis management, 304

- Aneurysm,  
  beta-blocker management of dissecting aneurysm, 18, 19  
  hypertension management, 113
- Angina pectoris,  
  aspirin therapy, 168, 169  
  beta-blocker therapy,  
    comparison with calcium channel blockers and oral nitrates, 3, 15, 16  
    contraindications, 163  
    dosing for cardioprotection, 162, 163  
    first-line treatment, 2, 3, 160–162  
    indications, 16  
    unstable angina, 171  
  calcium channel blocker management, 76, 77, 163, 164, 172  
  clinical features, 159  
  controversies, 177–179  
  hypertension management, 113  
  nitrates in management, 164–168  
  pathophysiology, 159, 160  
  Prinzmetal's angina, *see* Variant angina  
  treatment algorithm, 162  
  unstable angina, *see* Unstable angina
- Angioedema, angiotensin blockade  
  complication, 52, 146, 147
- Angiotensin receptor blockers (ARBs), *see also* specific drugs,  
  angiotensin-converting enzyme inhibitor  
    comparison trials, 58, 59, 63  
  combination therapy with angiotensin-converting enzyme inhibitors, 64, 65  
  contraindications, 50, 51  
  controversies, 63–65  
  dosing, 45  
  heart failure management, 48, 49, 65, 218–221, 244, 245  
  hypertension management,  
    action, 121  
    adverse effects, 121  
    contraindications, 122  
    overview, 47, 48  
    specific drugs, 122, 123  
  indications, 47–50  
  mechanism of action, 58  
  mortality reduction, 43  
  pharmacology, 45  
  trade names, 398
- Angiotensin-converting enzyme (ACE)  
  inhibitors, *see also* specific drugs,  
  adverse effects, 51–53, 146, 147  
  angiotensin-receptor blocker comparison trials, 58, 59, 63  
  classes, 43  
  combination therapy with angiotensin receptor blockers, 64, 65  
  comparison with other vasodilators, 46, 47  
  contraindications, 50, 51  
  controversies, 63–65  
  digoxin combination therapy, 227, 228  
  dosing, 44  
  drug interactions, 53, 364, 365  
  gene polymorphisms, 46  
  heart failure management, 48, 49, 65, 218–221, 244, 245  
  hypertension management,  
    action, 121  
    adverse effects, 121  
    contraindications, 122  
    overview, 47, 48  
    specific drugs, 122, 123  
  indications, 47–50  
  lactation safety, 358  
  mechanism of action, 43, 45, 46  
  mortality reduction, 43  
  myocardial infarction management, 195  
  pharmacology, 44, 53  
  pregnancy use for hypertension, 354, 356  
  trade names, 397, 398
- Antibiotics,  
  cardiac effects, 375  
  drug interactions, 372  
  infective endocarditis management,  
    drug selection guidelines, 299, 300  
    enterococcal endocarditis, 302  
    miscellaneous bacteria, 302, 303  
    prophylaxis, 305, 306  
    right-sided endocarditis, 303, 304  
    *Staphylococcus aureus* endocarditis,  
      native valve, 301  
      overview, 300, 301  
      prosthetic valve, 301  
    *Streptococcus viridans* and *S. bovis*  
      endocarditis,  
      native valve, 301  
      prosthetic valve, 301, 302  
  unstable angina management, 174
- Anticoagulants, *see* Heparin; Warfarin
- Antihistamines,  
  cardiac effects, 376  
  drug interactions, 372
- Antiplatelet agents, *see also* specific drugs,

- drug interactions, 368
- efficacy, 332
- indications, 331
- mechanism of action, 331, 332
- trade names, 399, 400
- APCs, *see* Atrial premature contractions
- ARBs, *see* Angiotensin receptor blockers
- Arrhythmias, *see also* specific arrhythmias
  - and drugs,
  - beta-blocker management, 16, 17
  - diagnosis,
    - narrow QRS complex arrhythmias, 251
    - wide QRS complex arrhythmias, 251–253
  - drugs,
    - classification of antiarrhythmic drugs, 250, 251
    - hallmark clinical trials, 389
    - trade names, 399
  - hypertension management, 113
  - myocardial infarction association and management, 197, 198
  - pregnancy and drug safety, 356, 357
  - rational therapy factors, 249
- Aspirin,
  - actions, 334, 335
  - angina management, 168, 169, 172
  - atrial fibrillation management, 262, 263
  - dosing, 335
  - drug interactions, 368
  - hallmark clinical trials, 390, 391
  - historical review, 332–334
  - indications, 333, 334
  - lactation safety, 359
  - myocardial infarction management, 185
  - overview, 332
  - unstable angina management, 172
- ASTEROID, findings, 387, 388
- Asystole, *see* Cardiac arrest
- Atenolol,
  - cardiovascular protection studies, 139, 140
  - dosing, 7, 8
  - hypertension management, 116
  - overview, 24
  - pharmacologic properties, 10
  - pregnancy use for hypertension, 351
  - selection guidelines, 31
  - trade names, 400
- Atorvastatin,
  - dosing, 314
  - drug interactions, 314
  - dyslipidemia management, 314
  - hallmark clinical trials, 387
  - trade names, 403
- Atrial fibrillation (AF),
  - hallmark clinical trials, 389
  - treatment,
    - anticoagulation, 262, 263
    - cardioversion, 261, 262
    - chronic atrial fibrillation, 261
    - paroxysmal atrial fibrillation, 261
    - rate control versus rhythm control, 262
    - recent onset, 260, 261
    - ventricular response, 260
- Atrial flutter, management, 259
- Atrial premature contractions (APCs), management, 258, 259
- Atrioventricular nodal reentrant tachycardia (AVNRT),
  - chronic management, 257, 258
  - clinical features, 253
  - termination of acute arrhythmia,
    - drugs, 254–257
    - physical maneuvers, 253
- Atropine,
  - arrhythmia management following myocardial infarction, 197, 198
  - indications, 293
  - overview, 293
- AVNRT, *see* Atrioventricular nodal reentrant tachycardia
- Azimilide, atrial fibrillation management, 261
- B**
- Bartter's syndrome, angiotensin blockade management, 50
- Benazepril,
  - dosing, 44, 123
  - overview, 56
  - pharmacology, 44
  - trade names, 397
- Bendrofluazide,
  - overview, 119
  - trade names and dosing, 86
- Bendroflumethiazide, trade names and dosing, 86, 402
- Benzthiazide, trade names and dosing, 86
- Beta-blockers, *see also* specific drugs,
  - acute myocardial infarction,
    - controversies, 40, 41
    - management, 17, 18, 187, 194, 195
  - angina management,

- comparison with calcium channel blockers and oral nitrates, 3, 15, 16
  - contraindications, 163
  - dosing for cardioprotection, 162, 163
  - first-line treatment, 2, 3, 160–162
  - indications, 16
    - unstable angina, 171
  - antiarrhythmic activity, 275
  - controversies,
    - diabetes, 38–40, 141–146
    - hypertension, 37, 38, 137–139
    - myocardial infarction, 40, 41
  - dosing, 7, 8
  - drug interactions, 23, 368, 369
  - efficacy in coronary heart disease, 2
  - features of specific drugs, 23–31
  - glucose intolerance induction studies, 38–40, 141–145, 389, 390
  - heart failure,
    - management, 18, 223–225
    - risks, 146
  - hypertension,
    - controversies,
      - elderly, 38
    - first-line management, 37, 38
    - management,
      - action, 115
      - dosing, 115
      - overview, 17
      - specific drugs, 116, 117
  - indications, 16–22
  - lactation safety, 359
  - mechanism of action, 6, 7
  - mortality reduction studies, 2, 4
  - pharmacological properties,
    - blood flow effects, 13
    - blood lipid effects, 2, 13
    - cardioselectivity, 8–11
    - intrinsic sympathomimetic activity, 11
    - lipid solubility, 12
    - liver metabolism, 12, 13
    - membrane-stabilizing activity, 12
    - plasma volume effects, 12
    - potassium effects, 13
    - renin interactions, 12
  - pregnancy use,
    - arrhythmias, 356, 357
    - heart failure, 355
    - hypertension, 351–353
  - receptors, *see*  $\beta$ -Adrenergic receptors
  - salutary effects, 2, 3, 13–15
  - selection guidelines, 31, 32
    - side effects, 22, 23
    - trade names, 400, 401
    - ventricular tachycardia management, 266
    - warnings and contraindications, 20, 22
  - Betaxolol, trade names, 400
  - Bezafibrate,
    - dyslipidemia management, 318
    - trade names, 404
  - Bicarbonate,
    - adverse effects, 292, 293
    - overview, 292
  - Bisoprolol,
    - dosing, 8
    - heart failure management, 225
    - hypertension management, 116, 117
    - overview, 24, 25
    - perioperative protection, 25
    - pharmacologic properties, 10
    - selection guidelines, 31, 32
    - trade names, 400
  - Bivalirudin,
    - hallmark clinical trials, 384, 385
    - overview, 344
  - BNP, *see* B-type natriuretic peptide
  - Bronchospasm, beta-blocker precautions, 8, 9
  - B-type natriuretic peptide (BNP), heart failure diagnosis, 246
  - Bumetamide,
    - heart failure management, 221
    - overview, 90
    - trade names and dosing, 86, 402
- ## C
- Calcium channel blockers, *see also* specific drugs,
    - adverse effects, 2, 4
    - angina management, 76, 77, 163, 164, 172
    - angina pectoris first-line treatment trials
      - versus beta-blockers, 3, 15, 16
    - channels,
      - beta-blocker interactions, 7
      - types, 7, 68
    - combination therapy, 77, 79
    - controversies,
      - heart failure, 81, 82
      - hypertension with coronary heart disease, 82, 83
    - drug interactions, 369, 370
    - hemodynamic and electrophysiologic effects, 68, 69
    - hypertension management, 124–126
    - indications, 75–78

- lactation safety, 359
  - mechanism of action, 67, 68
  - pregnancy use for hypertension, 354
  - selection guidelines, 75, 77
  - trade names, 401, 402
- Calcium chloride, cardiac arrest management, 294
- Candesartan,
  - dosing, 45, 123
  - hallmark clinical trials, 386
  - overview, 59
  - pharmacology, 45
  - trade names, 398
- Capozide, hypertension management, 124
- CAPRICORN, findings, 385
- Captopril,
  - dosing, 44, 54, 123
  - drug interactions, 53
  - heart failure management, 220
  - hypertension management,
    - dosing, 122
    - overview, 122
  - overview, 54
  - pharmacology, 44, 54
  - trade names, 397
- Cardiac arrest,
  - drug therapy, 290–294
  - life-saving procedures,
    - breathing, 288
    - cardiopulmonary resuscitation guidelines, 286
    - circulation, 287, 288
    - defibrillation, 289, 290
    - oxygen therapy, 289
    - precordial thump technique, 288, 289
    - responsiveness checking, 286
  - pathophysiology, 285, 286
- Cardiogenic shock, myocardial infarction association and management, 202–204
- Cardiopulmonary resuscitation (CPR), guidelines, 286
- Cardioversion, atrial fibrillation management, 261, 262
- Carotid sinus massage, arrhythmia termination, 253
- Carteolol, trade names, 400
- Carvedilol,
  - dosing, 8, 26
  - hallmark clinical trials, 385
  - heart failure management, 224
  - hypertension management, 117
  - indications, 26, 27
  - overview, 25, 26
  - pharmacologic properties, 10, 26
  - selection guidelines, 31, 32
  - trade names, 400
- CETi-1, cholesterol ester transfer protein vaccine, 328
- CETP, *see* Cholesterol ester transfer protein
- CHARISMA, 391
- CHARM, findings, 386
- Chloroquine, cardiac effects, 376
- Chlorothiazide, trade names and dosing, 86, 402
- Chlorthalidone, trade names and dosing, 86, 402
- Cholesterol,
  - absorption inhibitors, 316, 372
  - dyslipidemia, *see* Dyslipidemia
- Cholesterol ester transfer protein (CETP), CETi-1 vaccine, 328
- Cholestyramine,
  - drug interactions, 372
  - dyslipidemia management, 316
  - trade names, 404
- Cilazapril,
  - dosing, 44, 123
  - overview, 56
  - pharmacology, 44
  - trade names, 397
- Cimetidine, drug interactions, 372, 373
- Cisapride, drug interactions, 377
- Cisplatin, cardiac effects, 377
- Clonidine, hypertension management, 125, 126
- Clopidogrel,
  - angina management,
    - stable angina, 169
    - unstable angina management, 172
    - variant angina management, 177
  - aspirin combination therapy, 177, 178
  - clinical trials, 336, 337
  - drug interactions, 368
  - hallmark clinical trials, 336, 337, 390, 391
  - non-ST-elevation myocardial infarction management, 205, 206
  - overview, 336
  - trade names, 399
- Coarctation of the aorta, angiotensin blockade management, 50
- Colestipol,
  - dyslipidemia management, 316
  - trade names, 404
- COMMIT, findings, 390
- COMMIT/CCS-2, findings, 391
- COPERNICUS, findings, 385
- Corticosteroids, cardiac effects, 376

- Cough, angiotensin blockade complication, 51  
CPR, *see* Cardiopulmonary resuscitation  
Cyclopenthiiazide, trade names and dosing, 86  
Cyclophosphamide, cardiac effects, 377  
Cyclosporin, drug interactions, 373  
Cyclothiazide, trade names and dosing, 86
- D**
- Dalteparin, trade names, 399  
Defibrillation, cardiac arrest, 289, 290  
Depression, hypertension management, 115  
Diabetes,  
  angiotensin-converting enzyme inhibitor protection studies, 64  
  beta-blockers,  
    glucose intolerance induction studies, 38–40, 141–145, 389, 390  
    management, 20  
  diuretics and glucose intolerance induction studies, 141–146  
  hypertension management, 113  
  percutaneous coronary intervention, 176  
Diamorphine, myocardial infarction management, 187  
Diastolic heart failure, heart failure preserved ejection fraction management, 241–244  
Diazoxide, hypertensive emergency management, 132  
Diet, *see* Lifestyle modification  
Digoxin,  
  angiotensin-converting enzyme combination therapy, 227, 228  
  atrial fibrillation management, 261, 262  
  atrioventricular nodal reentrant tachycardia management, 257  
  CHARM-Preserved study, 244  
  dosing, 228, 229  
  drug interactions, 230, 370  
  heart failure preserved ejection fraction management, 243, 244  
  herb interactions, 378  
  indications, 225, 226  
  lactation safety, 359, 360  
  mechanism of action, 228  
  monitoring, 229, 230  
  overview, 225  
  pregnancy use for heart failure, 355  
  study analysis, 226, 227  
  toxicity,  
    management, 231, 232  
    symptoms, 230, 231  
  trade names, 402
- Diltiazem,  
  action, 72, 73  
  adverse effects, 73  
  angina management, 164  
  atrial fibrillation management, 260  
  atrioventricular nodal reentrant tachycardia management, 257  
  drug interactions, 73  
  hypertension management, 125  
  overview, 72  
  trade names, 401
- Dipyridamole,  
  action, 269  
  adverse effects, 269, 270  
  dosing, 269  
  drug interactions, 335, 366  
  indications, 269, 335, 336  
  lactation safety, 360  
  overview, 269, 335  
  pharmacokinetics, 269  
  pregnancy and drug safety, 357  
  trade names, 399, 400
- Diuretics, *see also* specific drugs,  
  dosing, 86  
  drug interactions, 370, 371  
  glucose intolerance induction studies, 141–146  
  heart failure,  
    management, 221  
    risks, 146  
  hypertension management, 117–120  
  indications, 85  
  lactation safety, 360  
  loop diuretics,  
    action, 88  
    adverse effects, 89  
    contraindications, 89  
    dosing, 87, 88  
    drug interactions, 89, 90  
    examples, 90, 91  
    intravenous indications, 88, 89  
    mechanism of action, 87  
    pharmacokinetics, 88  
    selection guidelines, 98, 99  
  monitoring, 85, 87  
  potassium-sparing diuretics,  
    advantages, 92, 93  
    combination therapy, 93, 94  
    contraindications, 92  
    disadvantages, 93  
    indications, 91, 92



- mechanism of action, 91
  - warnings, 92, 94
  - potassium supplements, 95–98
  - pregnancy use for heart failure, 355, 356
  - thiazide diuretics and pregnancy use for hypertension, 353
  - trade names, 86, 402, 403
- Divistyramine, dyslipidemia management, 316
- Dobutamine,
- cardiogenic shock management, 203, 204
  - heart failure management, 199, 200, 233
  - infusion pump chart, 200
- Dofetilide, atrial fibrillation management, 260, 61
- Dopamine,
- cardiogenic shock management, 203, 204
  - heart failure management following myocardial infarction, 199
  - infusion pump chart, 201, 395
- Doxazosin, warnings, 133
- Doxorubicin, cardiac effects, 377
- Drug interactions, *see also* specific drugs, pharmacodynamic interactions, 363
- Dyazide,
- formulation and dosing, 93
  - hypertension management, 119, 120
- Dyslipidemia, *see also* Statins,
- beta-blockers and blood lipid effects, 2, 13
  - diagnosis, 308
  - diet modification, 309–311
  - drug therapy,
    - cholesterol absorption inhibitors, 316
    - combination therapy, 315
    - fibrates, 317, 318
    - guidelines, 308, 311, 318, 320
    - nicotinic acid, 316, 317
    - statins, 311–315, 319
  - hypertension management, 114
  - lipoproteins,
    - conversion calculations, 308
    - goals, 307, 308
    - secondary causes, 308, 309
- Dytide, formulation and dosing, 93
- E**
- Ebtifibatide, trade names, 400
- Enalapril,
- dosing, 44, 55, 123
  - heart failure management, 220
  - hypertension management,
    - dosing, 123, 124
    - overview, 123
  - overview, 55
  - pharmacology, 44, 55
  - trade names, 397
- Enalaprilat, hypertensive emergency management, 129, 133
- Endocarditis, *see* Infective endocarditis
- Endothelin-1, beta blocker effects on levels, 6
- Enoxaparin,
- adverse effects, 344
  - hallmark clinical trials, 381–383
  - monitoring, 344
  - myocardial infarction management, 193
  - overview, 343
  - trade names, 399
- Enterococcal endocarditis, *see* Infective endocarditis
- EPHESUS, findings, 385, 386
- Epinephrine,
- dosing, 291, 292
  - indications, 292
  - overview, 291
- Eplerenone,
- hallmark clinical trials, 385, 386
  - heart failure management, 222, 223
  - hypertension management, 120
  - indications, 99
- Eprosartan,
- dosing in hypertension, 123
  - overview, 60
  - trade names, 398
- Eptifibatide,
- dosing, 340
  - indications, 340
  - non-ST-elevation myocardial infarction management, 205
  - properties, 338
  - unstable angina management, 174
- Ergotamine, cardiac effects, 376
- Erythromycin, cardiac effects, 375
- Esmolol,
- action, 27
  - atrial fibrillation management, 260
  - dosing, 27
  - hypertensive emergency management, 129
  - indications and contraindications, 27
  - overview, 27
  - trade names, 400
- Ethacrynic acid,
- overview, 90
  - trade names and dosing, 86
- ExTRACT-TIMI 25, findings, 382, 383
- Ezetimibe, dyslipidemia management, 316, 320

**F**

- Felodipine,  
hypertension management, 125  
overview, 74  
trade names, 401
- Fenofibrate,  
dyslipidemia management, 318, 327, 328  
trade names, 404
- Fenoldopam, hypertensive emergency management,  
action, 131  
indications, 129
- Fibrates,  
dyslipidemia management, 317, 318  
prospects in cardiovascular disease management, 327, 328  
trade names, 404
- Flecainide,  
action, 274  
adverse effects, 274  
atrioventricular nodal reentrant tachycardia management, 258  
dosing, 273  
drug interactions, 366  
overview, 273  
pharmacokinetics, 274  
trade names, 399
- 5-Fluorouracil, cardiac effects, 377
- Fluvastatin, trade names, 403
- Folic acid, homocysteine lowering trials, 391, 392
- Fondaparinux,  
hallmark clinical trials, 381, 382  
myocardial infarction management, 193, 194  
overview, 345
- Foscarnet, cardiac effects, 376
- Fosinopril,  
dosing, 44, 56, 123  
overview, 56  
pharmacology, 44  
trade names, 397
- Frumil, formulation and dosing, 93
- Frusemide, *see* Furosemide
- Frusine, formulation and dosing, 93
- Furosemide,  
action, 88  
adverse effects, 89  
contraindications, 89  
dosing, 86–88  
drug interactions, 89, 90  
heart failure management, 198, 199, 221

- hypertension management, 120  
intravenous indications, 88, 89  
overview, 87  
pharmacokinetics, 88  
pulmonary edema management, 236  
trade names, 403

**G**

- Gatifloxacin, unstable angina management, 174
- Gemfibrozil,  
adverse effects, 317, 318  
overview, 317  
trade names, 404
- GEMINI, findings, 389, 390
- Gentamicin, right-sided endocarditis management, 303, 304
- Glycoprotein IIb/IIIa receptor blockers, *see also* specific drugs,  
mechanism of action, 337, 339  
types and properties, 338  
unstable angina management, 173, 174
- Gout, hypertension management, 115
- Grapefruit juice, drug interactions, 378

**H**

- Halofantrine,  
cardiac effects, 375  
drug interactions, 372
- Heart failure,  
aldosterone antagonist therapy, 98, 99, 222, 223, 245  
angiotensin blockade in management, 48, 49, 65, 218–221, 244, 245  
antihypertensive association studies, 146  
beta-blocker therapy, 18, 223–225  
black patients, 245, 246  
calcium channel blocker management, 81, 82  
diagnosis, 214–216  
digoxin therapy,  
angiotensin-converting enzyme combination therapy, 227, 228  
dosing, 228, 229  
drug interactions, 230  
indications, 225, 226  
mechanism of action, 228  
monitoring, 229, 230  
study analysis, 226, 227  
toxicity,  
management, 231, 232  
symptoms, 230, 231  
diuretic therapy, 221

- dobutamine therapy, 233
  - epidemiology, 211
  - etiology, 211–213
  - guidelines for management, 217, 218
  - hallmark clinical trials, 385, 386
  - heart failure preserved ejection fraction management, 241–243
  - hypertension management, 114
  - infective endocarditis, 305
  - myocardial infarction association and management, 198–201, 219, 220
  - natriuretic peptides in diagnosis, 246
  - nesiritide, 246
  - pathophysiology, 216, 217
  - precipitating factors, 213, 214, 217
  - pulmonary edema management, 236, 237
  - statin therapy, 247, 327
  - treatment guidelines by stage, 233–235
- Heparin,
- action, 343
  - adverse effects, 343
  - hallmark clinical trials, 382–384
  - infusion pump chart, 396
  - low-molecular-weight heparin, 343, 344
  - myocardial infarction management, 193, 194
  - thrombolytic therapy adjunct, 191
  - unstable angina management, 172, 173
- Hirudin, overview, 344, 345
- HOPE, findings, 386
- HOPE-2, findings, 391, 392
- Hydralazine,
- hallmark clinical trials, 386
  - heart failure management, 47, 221
  - hypertensive emergency management, dosing, 132
  - indications, 129
  - pregnancy use for hypertension, adverse effects, 353
  - dosing, 353
  - hypertensive emergencies, 353
  - overview, 352, 353
- Hydrochlorothiazide,
- hypertension management, action, 117
  - adverse effects, 117–119
  - trade names and dosing, 86, 117, 403
- Hydroflumethiazide, trade names and dosing, 86
- Hypertension,
- age and ethnicity in drug selection, 147–154
  - alpha<sub>1</sub>-blocker management, 126, 127
  - angiotensin blockade therapy, action, 121
  - adverse effects, 121
  - contraindications, 122
  - overview, 47, 48
  - specific drugs, 122, 123
- beta-blockers,
- controversies, elderly, 38
  - first-line management, 37, 38, 137–139
  - management, action, 115
  - dosing, 115
  - overview, 17
  - specific drugs, 116, 117
- blood pressure classification, 105, 106
- calcium channel blocker management, 82, 83, 124–126
- centrally acting drug management, 125, 126
- clinical trial design, 154
- detrimental effects, 104
- diuretic management, 117–120
- drug selection,
- comorbid conditions, 113–115
  - older patients, 109–113
  - younger patients, 107–109
- emergency management, 127–129
- epidemiology, 103
- hallmark clinical trials, 386, 387
- isolated systolic hypertension, 105
- laboratory work-up, 107
- lifestyle modification in management, 106
- pharmacotherapy limitations, 103
- pregnant patient management, 115, 349–355
- risk stratification, 104, 105
- secondary hypertension causes, 106, 107
- urgency management, 129
- Hyperthyroidism, hypertension management, 115
- Hypertrophic cardiomyopathy, beta-blocker management, 19
- Hypoglycemia, beta-blocker precautions, 11
- Hyzaar, hypertension management, 124
- ## I
- Ibutilide, atrial fibrillation management, 260
- IE, *see* Infective endocarditis
- Indapamide, trade names and dosing, 86, 403
- Infective endocarditis (IE),
- antibiotic therapy, drug selection guidelines, 299, 300

- enterococcal endocarditis, 302
- miscellaneous bacteria, 302, 303
- prophylaxis, 305, 306
- right-sided endocarditis, 303, 304
- Staphylococcus aureus* endocarditis,
  - native valve, 301
  - overview, 300, 301
  - prosthetic valve, 301
- Streptococcus viridans* and *S. bovis* endocarditis,
  - native valve, 301
  - prosthetic valve, 301, 302
- anticoagulant therapy, 304
- blood culture for organism identification, 298, 299
- classification, 297
- diagnosis, 297, 298
- etiology, 297
- fungal endocarditis management, 304
- precipitating factors, 298
- surgery indications, 298, 304, 305
- Intrinsic sympathomimetic activity (ISA),
  - beta-blockers, 11
- Irbesartan,
  - dosing, 45, 123
  - overview, 59
  - pharmacology, 45
  - trade names, 398
- ISA, *see* Intrinsic sympathomimetic activity
- Isosorbide dinitrate,
  - angina management, 166, 167
  - hallmark clinical trials, 386
  - trade names, 404
- Israpidine,
  - overview, 73
  - trade names, 401, 402
- L**
- Labetalol,
  - hypertensive emergency management,
    - dosing, 131, 132
    - indications, 129
  - overview, 27, 28
  - pregnancy use for hypertension, 352
  - trade names, 400
- Lactation,
  - cardiac drug safety, 357–360
  - drug excretion factors, 357, 358
- Lamifiban,
  - properties, 338
  - unstable angina management, 174
- Lidocaine,
  - action, 271
  - adverse effects, 272
- arrhythmia management following
  - myocardial infarction, 197, 198
- cardiac arrest management, 291, 293
- dosing, 271, 293
- drug interactions, 366, 367
- indications, 271, 272
- lactation safety, 360
- overview, 271
- pharmacokinetics, 271
- pregnancy and drug safety, 357
- ventricular tachycardia management, 266
- Lifestyle modification,
  - dyslipidemia and diet, 309–311
  - hypertension management, 106
- LIPID, findings, 389
- Lisinopril,
  - dosing, 44, 56, 123
  - heart failure management, 220, 221
  - overview, 55
  - pharmacology, 44, 56
  - trade names, 397
- Lithium, drug interactions, 373
- Long QT syndromes, beta-blocker management, 18
- Loop diuretics, *see* Diuretics; specific drugs
- Losartan,
  - dosing, 45, 123
  - overview, 59
  - pharmacology, 45
  - trade names, 398
- Lovastatin,
  - dosing, 313
  - dyslipidemia management, 313
  - trade names, 403
- M**
- Magnesium,
  - cardiac arrest management, 291, 294
  - myocardial infarction management, 196, 197
  - pregnancy use for hypertension, 354, 355
  - torsades de pointes management, 267, 268
- Marfan's syndrome, beta-blocker management, 19
- Maxzide, formulation and dosing, 93
- Mefloquine, drug interactions, 372
- Membrane-stabilizing activity (MSA), beta-blockers, 12
- Meperidine, myocardial infarction management, 187
- MERIT-HF, findings, 385
- Methylclothiazide, trade names and dosing, 86

- Methyldopa,  
hypertension management, 126  
lactation safety, 360  
pregnancy use for hypertension, 350
- Metoclopramide, cardiac effects, 376
- Metolazone,  
heart failure management, 221  
overview, 94  
trade names and dosing, 86, 403
- Metoprolol,  
angina management, 162  
dosing, 8  
hallmark clinical trials, 385  
hallmark clinical trials, 391  
heart failure management, 224, 225  
hypertension management, 116  
mortality reduction studies, 4  
overview, 28  
pharmacologic properties, 10  
pregnancy use for hypertension, 351  
selection guidelines, 31, 32  
trade names, 400, 401
- Mexiletine,  
action, 272  
adverse effects, 272, 273  
dosing, 272  
drug interactions, 367  
lactation safety, 360  
overview, 272  
pharmacokinetics, 272  
trade names, 399
- MI, *see* Myocardial infarction
- Mibefradil, withdrawal from market, 67, 74
- Mitral regurgitation, beta-blocker management, 19
- Mitral stenosis, beta-blocker management, 19
- Mitral valve prolapse,  
beta-blocker management, 19  
hypertension management, 115
- Moduretic,  
formulation and dosing, 93, 120  
hypertension management, 120
- Moexipril, trade names, 397, 398
- Monoamine oxidase inhibitors, drug interactions, 374
- Morphine,  
myocardial infarction management, 186, 187  
pulmonary edema management, 236  
unstable angina management, 170
- MRC/BHF Heart Protection Study, findings, 388
- MSA, *see* Membrane-stabilizing activity
- Müller maneuver, arrhythmia termination, 253
- Multifocal atrial tachycardia, management, 258
- Myocardial infarction (MI),  
angiotensin blockade in management, 49, 50, 195  
aspirin therapy, 185  
beta-blockers and acute myocardial infarction, controversies, 40, 41  
management, 17, 18, 187, 194, 195  
complications and management, arrhythmias, 197, 198  
cardiogenic shock, 202–204  
heart failure, 198–201  
right ventricular infarction, 201, 202  
diagnosis, 183  
genetics, 183, 184  
guideline changes, 206, 207  
heparin therapy, 191, 193, 194  
infarct size-limiting interventions, 188  
magnesium therapy, 196, 197  
monitoring, 187, 188  
nitrate therapy, 195, 196  
non-ST-elevation myocardial infarction management, 204–206  
oxygen therapy, 187  
pain management, 186, 187  
percutaneous coronary intervention, 186, 188, 189  
statin therapy, 196  
thrombolytic therapy, 186, 189–191
- Myocardial ischemia, *see* Angina pectoris
- ## N
- Nadolol,  
dosing, 7, 8, 28, 29  
overview, 28  
pharmacologic properties, 10  
trade names, 401
- Nebivolol, overview, 31
- Nesiritide, heart failure management studies, 246
- Neurocardiogenic syncope, beta-blocker management, 20
- Neutropenia, angiotensin blockade complication, 52, 59
- Niacin, *see* Nicotinic acid
- Nicardipine,  
hypertensive emergency management, 129  
overview, 74  
trade names, 402

- Nicorandil, angina management, 178, 179
- Nicotinic acid,  
adverse effects, 317  
dosing, 316, 317
- Nifedipine,  
action, 69  
adverse effects, 69–71  
drug interactions, 71  
hypertension management, 124  
overview, 69  
pregnancy use for hypertension, 354  
trade names, 402
- Nimodipine,  
dosing, 74  
hypertensive emergency management,  
129, 133  
overview, 74
- Nisoldipine,  
overview, 74  
trade names, 402
- Nitrates, *see also* specific drugs,  
action, 164  
angina management,  
cutaneous nitroglycerin, 165, 166  
intravenous nitroglycerin, 167, 168  
isosorbide dinitrate, 166, 167  
oral nitroglycerin, 164  
angina pectoris first-line treatment trials  
versus beta-blockers, 3, 15, 16  
calcium channel blocker combination  
therapy, 79  
drug interactions, 371  
myocardial infarction management, 195, 196  
tolerance, 166  
trade names, 404  
types and trade names, 165  
unstable angina management, 171
- Nitroglycerin,  
action, 164  
cutaneous nitroglycerin, 165, 166  
dosing, 164  
heart failure management, 47  
hypertensive emergency management, 129  
intravenous nitroglycerin, 167, 168  
overview, 164  
pulmonary edema management, 236  
trade names, 404
- Nitroprusside,  
heart failure management following  
myocardial infarction, 199  
hypertensive emergency management,  
action and metabolism, 130  
adverse effects, 130, 131  
contraindications, 130  
dosing, 130  
indications, 129  
infusion pump chart, 202, 396
- Nonsteroidal anti-inflammatory drugs  
(NSAIDs), drug interactions, 373
- NSAIDs, *see* Nonsteroidal anti-inflamma-  
tory drugs
- O**
- OASIS-5, findings, 381, 382
- OASIS-6, findings, 382
- Olmесartan, trade names, 398
- Organophosphates, cardiac effects, 376
- Osteoporosis, hypertension management, 115
- Oxprenolol,  
smoking effects, 112  
trade names, 401
- Oxygen therapy,  
cardiac arrest, 289  
heart failure management following  
myocardial infarction, 199  
myocardial infarction management, 187
- P**
- Paroxysmal atrial tachycardia (PAT), man-  
agement, 258
- PAT, *see* Paroxysmal atrial tachycardia
- PCI, *see* Percutaneous coronary intervention
- PCI-CLARITY, findings, 390
- Percutaneous coronary intervention (PCI),  
beta-blocker management, 18  
myocardial infarction management, 186,  
188, 189  
non-ST-elevation myocardial infarction  
management, 205, 206
- Perindopril,  
dosing, 44, 123  
overview, 57  
pharmacology, 44  
trade names, 398
- Peripheral vascular disease,  
beta-blocker precautions, 9  
hypertension management, 115
- Phenothiazines, drug interactions, 373
- Phenoxybenzamine, hypertension management,  
127
- Phentolamine, hypertension management,  
127
- Phenylephrine, atrioventricular nodal reentrant  
tachycardia management, 257

- Phenytoin,  
  action, 273  
  adverse effects, 273  
  dosing, 273  
  drug interactions, 367  
  indications, 273  
  overview, 273  
  pharmacokinetics, 273  
  pregnancy and drug safety, 357
- Piretanide, trade names and dosing, 86
- Plasma volume, beta-blocker effects, 12
- Polythiazide, trade names and dosing, 86
- Potassium,  
  angiotensin blockade and hyperkalemia  
    complication, 51  
  beta-blocker effects, 13  
  intravenous potassium chloride guidelines,  
    96, 97  
  supplementation in diuretic patients,  
    monitoring, 96, 98  
    potassium chloride, 95, 96  
    salt substitutes, 96
- Potassium-sparing diuretics, *see* Diuretics;  
  specific drugs
- Pravastatin,  
  dosing, 313  
  dyslipidemia management, 313, 314  
  hallmark clinical trials, 389  
  trade names, 403
- Prazosin, heart failure management, 47
- Precordial thump, technique, 288, 289
- Pregnancy,  
  arrhythmia management, 356, 357  
  cardiovascular drug guidelines, 349  
  heart failure management, 355, 356  
  hypertension management, 115, 349–355
- Premature ventricular contractions (PVCs),  
  management, 264
- Prinzmetal's angina, *see* Variant angina
- Procainamide,  
  action, 270  
  adverse effects, 270  
  cardiac arrest management, 291  
  dosing, 270  
  drug interactions, 367  
  indications, 270  
  overview, 270  
  pharmacokinetics, 270  
  trade names, 399
- Propafenone,  
  action, 274  
  adverse effects, 275  
  contraindications, 275  
  dosing, 274  
  drug interactions, 367  
  overview, 274  
  pharmacokinetics, 274, 275  
  trade names, 399
- Propranolol,  
  angina management, 162  
  atrioventricular nodal reentrant tachycardia  
    management, 257  
  cardiac arrest management, 294  
  dosing, 7, 8  
  indications, 29  
  mortality reduction studies, 4  
  overview, 29  
  pharmacologic properties, 10  
  smoking effects, 112  
  trade names, 401
- PROSPER, findings, 389
- Proteinuria, angiotensin blockade complication,  
  52
- PROV IT-TIMI 22, findings, 387
- Pulmonary edema, management, 236, 237
- Pulmonary hypertension, angiotensin blockade  
  management, 50
- PVCs, *see* Premature ventricular contrac-  
  tions
- Q**
- Quinapril,  
  dosing, 44, 123  
  overview, 57  
  pharmacology, 44  
  trade names, 398
- Quinethazone, trade names and dosing, 86
- Quinidine,  
  action, 268  
  adverse effects, 268  
  dosing, 268  
  drug interactions, 367, 368  
  overview, 268  
  pharmacokinetics, 268  
  pregnancy and drug safety, 357  
  trade names, 399
- Quinine, drug interactions, 372
- R**
- RALES, findings, 385
- Ramipril,  
  dosing, 44, 123  
  hallmark clinical trials, 386  
  overview, 57  
  pharmacology, 44



- trade names, 398
- Ranazoline, angina management, 178
- Rash, angiotensin blockade complication, 52
- Renal insufficiency, hypertension management, 114
- Renin, beta-blocker interactions, 11, 12
- Renoprotection, angiotensin blockade, 50, 63, 64
- Retepase, overview, 192, 193
- Rosuvastatin,
  - dosing, 314
  - dyslipidemia management, 314, 315
  - trade names, 403
- S**
- Saint John's Wort, drug interactions, 378
- Scleroderma renal crisis, angiotensin blockade management, 50
- Selective serotonin reuptake inhibitors (SSRIs),
  - cardiac effects, 376
  - drug interactions, 373, 374
- Sildenafil, drug interactions, 377, 378
- Simvastatin,
  - dosing, 313
  - dyslipidemia management, 313
  - trade names, 404
- Smoking, beta-blocker effects, 112
- Sodium bicarbonate, *see* Bicarbonate
- Sodium nitroprusside, *see* Nitroprusside
- Sotalol,
  - action, 276
  - adverse effects, 276, 277
  - dosing, 7, 8, 276
  - indications, 276
  - indications and contraindications, 30
  - overview, 30
  - overview, 276
  - pharmacologic properties, 10
  - trade names, 399, 401
- Spiramycin, cardiac effects, 375
- Spirapril, overview, 57
- Spironolactone,
  - advantages, 92, 93
  - disadvantages, 92, 93
  - hallmark clinical trials, 385
  - heart failure management, 222, 223
  - indications, 91, 92
  - overview, 92
  - trade names and dosing, 86, 403
- SSRIs, *see* Selective serotonin reuptake inhibitors
- Staphylococcus aureus* endocarditis, *see* Infective endocarditis
- Statins, *see also* specific drugs,
  - adverse effects, 312, 313
  - clinical trial outcomes, 319
  - combination therapies, 315
  - contraindications, 312
  - controversies,
    - drug interactions, 326, 327
    - high-intensity therapy and atheroma regression, 323, 324, 387, 388
    - low-density cholesterol targets, 324
  - malignant arrhythmia management, 327
  - rhabdomyolysis, 324–325
  - differences between drugs, 312
  - drug interactions, 325–327, 371
  - hallmark clinical trials, 387–389
  - heart failure management, 247, 327
  - myocardial infarction management, 196
  - overview, 311, 312
  - pharmacokinetics, 325
  - pleiotropic effects, 311
  - trade names, 403, 404
  - unstable angina management, 173
- Streptococcus bovis* endocarditis, *see* Infective endocarditis
- Streptococcus viridans* endocarditis, *see* Infective endocarditis
- Streptokinase,
  - action, 191
  - adverse effects, 192
  - drug interactions, 192
  - overview, 191
- Stroke, hypertension management, 114
- Subarachnoid hemorrhage,
  - beta-blocker management, 20
  - hypertension management, 115
- Sudden cardiac death, *see* Cardiac arrest
- Sumatriptan, cardiac effects, 376
- Supraventricular arrhythmia, *see* Atrial flutter; Atrial fibrillation; Atrial premature contractions; Atrioventricular nodal reentrant tachycardia; Multifocal atrial tachycardia; Paroxysmal atrial tachycardia; Wolff-Parkinson-White syndrome



**T**

- TACTICS-TMI 18, findings, 384
- Taste loss, angiotensin blockade complication, 52
- TDP, *see* Torsades de pointes
- Telmisartan,  
overview, 59  
trade names, 398
- Tenecteplase, overview, 192
- Terazosin, hypertension management, 126, 127
- Terbutaline, cardiac effects, 376
- Tetralogy of Fallot, beta-blocker management, 19
- Theophylline, drug interactions, 374
- Thrombolytic therapy, *see also* specific agents,  
contraindications, 191  
myocardial infarction management, 186, 189–191
- Thyroxine, drug interactions, 375
- Timolol,  
angina management, 162  
dosing, 8  
mortality reduction studies, 4  
overview, 30, 31  
pharmacologic properties, 10  
trade names, 401
- Tirofiban,  
dosing, 340  
hallmark clinical trials, 384  
indications, 340, 341  
non-ST-elevation myocardial infarction management, 205  
properties, 338  
trade names, 400  
unstable angina management, 173, 174
- Tissue plasminogen activator (t-PA),  
action, 192  
drug interactions, 372  
overview, 192
- Tobramycin, right-sided endocarditis management, 303, 304
- ToprolXL, advantages, 28
- Torsades de pointes (TDP), management, 267, 268
- Torseamide,  
advantages, 98  
heart failure management, 221  
overview, 90, 91  
trade names and dosing, 86, 403

- t-PA, *see* Tissue plasminogen activator
- Trandolapril,  
dosing, 44, 123  
overview, 57, 58  
pharmacology, 44  
trade names, 398
- Triamterene, trade names and dosing, 86
- Trichlormethiazide, trade names and dosing, 86
- Tricyclic antidepressants,  
cardiac effects, 376  
drug interactions, 373
- U**
- Unstable angina,  
acute coronary syndrome terminology, 169  
hallmark clinical trials in acute coronary syndromes, 381–385  
laboratory work-up, 169, 170  
management,  
antibiotics, 174, 175  
aspirin, 172  
beta-blockers, 171  
calcium channel blockers, 172  
clopidogrel, 172  
glycoprotein IIb/IIIa receptor blockers, 173, 174  
heparin, 172, 173  
intravenous nitroglycerin, 167, 168  
pain, 170, 171  
statins, 173  
athophysiology, 169  
risk stratification, 170
- Urapidil, hypertensive emergency management, 129, 132
- V**
- Valsartan,  
dosing, 45, 123  
overview, 59  
pharmacology, 45  
trade names, 398
- Variant angina,  
diagnosis, 175  
treatment,  
percutaneous coronary intervention, 176  
pharmacotherapy, 175
- Vasalva maneuver, arrhythmia termination, 253

- Vaseretic, hypertension management, 124
  - Vasopressin, cardiac arrest management, 292
  - Ventricular fibrillation,
    - cardiac arrest, 285
    - survivor management, 266
  - Ventricular tachycardia (VT),
    - cardiac arrest, 285
    - diagnosis, 264
    - management,
      - algorithm, 265
      - drugs, 266
    - recurrent sustained tachycardia, 266, 267
  - Verapamil,
    - action, 71
    - adverse effects, 71, 72
    - angina management, 164
    - atrioventricular nodal reentrant tachycardia
      - management, 254, 257, 258
    - combination therapy, 77
    - contraindications, 254, 257
    - drug interactions, 72
    - hypertension management, 125
    - overview, 71
    - trade names, 402
  - Vincristine, cardiac effects, 377
  - VT, *see* Ventricular tachycardia
- W**
- Warfarin,
    - atrial fibrillation management, 262, 263
    - dosing, 341
    - drug interactions, 342
    - endocarditis management, 304
    - lactation safety, 359
    - overview, 341
    - trade names, 399
    - vitamin K antagonism and food content,
      - 341, 343
  - Wolff-Parkinson-White syndrome, arrhythmia
    - management, 263, 264
- Z**
- Zofenopril, overview, 58